SyntekaBio, Inc. (KOSDAQ: 226330)

Market Cap	85.29B
Revenue (ttm)	122.33M
Net Income (ttm)	-16.38B
Shares Out	15.26M
EPS (ttm)	-1,074.48
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	117,799
Open	6,070.00
Previous Close	6,260.00
Day's Range	5,990.00 - 6,350.00
52-Week Range	4,195.00 - 14,880.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 21, 2025

About SyntekaBio

SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, disease susceptibility, immune typing, pharmacogenomic typing, and multi-omics information-based drug side effect prediction technology. The company was ...

• Industry: Computer Programming, Data Processing, And Other Computer Related Services
• Founded: 2009
• Employees: 62
• Stock Exchange: KOSDAQ
• Ticker Symbol: 226330

Financial Performance

In 2023, SyntekaBio's revenue was 123.41 million, a decrease of -49.42% compared to the previous year's 243.99 million. Losses were -11.40 billion, 152.9% more than in 2022.